drugset / Trial / NCT03387566
A Study of Single Intravitreal Injection HB002.1M in Subjects With Neovascular Age-Related Macular Degeneration
Non-randomizedSequentialOpen-labelTreatment
Summary
The objectives of this study are to evaluate the safety, tolerability, and pharmacokinetic profile of HB002.1M, a human immunoglobulin Fc fusion protein containing domain 2 and flanking sequence of vascular endothelial growth factor (VEGF) receptor-1 in subjects with age-related macular degeneration (AMD).
Timeline
- Start
- 2018-02-08
- Primary completion
- 2020-02-01
- Completion
- 2020-03-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HB002.1M | Protein / enzyme biologic | 0.3 mg | Intravitreal |
| Subject | HB002.1M | Protein / enzyme biologic | 0.5 mg | Intravitreal |
| Subject | HB002.1M | Protein / enzyme biologic | 1 mg | Intravitreal |
| Subject | HB002.1M | Protein / enzyme biologic | 2 mg | Intravitreal |
| Subject | HB002.1M | Protein / enzyme biologic | 3 mg | Intravitreal |